Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Raphael, J. H.
Right arrow Articles by Kitas, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raphael, J. H.
Right arrow Articles by Kitas, G. D.
Related Collections
Right arrow Fibromyalgia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2003; 42: 185-186
© 2003 British Society for Rheumatology

Letters to the Editor

Adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome

J. H. Raphael, J. L. Southall and G. D. Kitas1

Departments of Pain Management and
1 Rheumatology, Dudley Group of Hospitals NHS Trust, West Midlands, UK

The first 10% of the full text of this article appears below.

SIR, Fibromyalgia is poorly understood in neurobiological terms, with no general agreement about its aetiology and pathogenesis. The symmetry of the condition leads to the hypothesis of a central nervous system disturbance [1]. In neuropathic pain states, it has been shown that inhibition of the pain pathway can be achieved by systemic administration of local anaesthetics such as intravenous lignocaine [2, 3].

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?